Biological modifier therapy for the treatment of rheumatoid arthritis

American Journal of the Medical Sciences

Volumn 323, Issue 4, 2002, Pages 197-205

  Jenkins, John K ^a   Hardy, Kenneth J ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Rheumatology Section   (United States)

Author keywords

Etanercept; IL 1; IL 1Ra; Infliximab; Rheumatoid arthritis; TNF

Indexed keywords

ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1BETA; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; HUMAN; INFECTION; INJECTION PAIN; PATHOGENESIS; RHEUMATOID ARTHRITIS;

EID: 0036083360     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200204000-00006     Document Type: Article

References (44)

1. The pathogenesis of rheumatoid arthritis: A guide to therapy
2. The role of tumor necrosis factor in health and disease
3. Rational use of new and existing disease-modifying agents in rheumatoid arthritis
4. Biologic basis for interleukin-1 in disease
5. Tumor necrosis factor α blockade in the treatment of rheumatoid arthritis
6. Localization of tumor necrosis factor α in synovial tissues and at the cartilage pannus junction in patients with rheumatoid arthritis
7. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
8. The pathogenesis of rheumatoid arthritis: The role of synoviocytes
9. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis
10. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor α in the knee joints of patients with rheumatoid arthritis
11. The role of cytokines in the pathogenesis of rheumatoid arthritis
12. IL-1 receptor antagonist and IL-1-beta production in human monocytes are regulated differently
13. Interleukin-1 receptor antagonist: Role in biology
14. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis
15. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 antagonist-deficient mice
16. Increased production of intracellular interluekin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: A possible role in the resolution of arthritis
17. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
18. Synergy between anti CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis
19. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra
20. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PGEylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis
21. A double-blind randomized, six arm, parallel group, dose finding, double dummy, multi-center comparison of sTNF p5-IgG (R045-2081-1enercept) subcutaneous to reference treatment with oral methotrexate (MTX) and their combination in patients with rheumatoid arthritis
22. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis receptor (p75)-Fc fusion protein
23. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
24. Etanercept in children with polyarticular juvenile rheumatoid arthritis
25. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
26. Epidemiology of aplastic anemia in France: A case-control study. I. Medical history and medication use
27. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: By what mechanisms could tumor necrosis factor α improve rheumatoid arthritis but exacerbate multiple sclerosis?
28. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
29. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
30. Infliximab: A review of its use in the management of rheumatoid arthritis
31. Repeated therapy with monoclonal antibody to tumor necrosis factor α in patients with rheumatoid arthritis
32. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
33. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose methotrexate in rheumatoid arthritis
34. Randomized phase III trial of infliximab (chimeric anti-TNFα monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate
35. Chimeric tumor necrosis factor α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
36. Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody
37. Doserange and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
38. Treatment of rheumatoid arthritis with recombinant human IL-1 receptor antagonist
39. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
40. Potential biologic agents for treating rheumatoid arthritis
41. Suppression of monocyte function and differential regulation of IL-1 and IL-1Ra by IL-4 contribute to resolution of experimental arthritis
42. Enhancement of T-cell mediated arthritis by treatment with monoclonal antibody against interleukin-4
43. RhuIL-4 in subjects with active rheumatoid arthritis (RA): A phase I dose escalating safety study